Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

May 11, 2021 by Alan Khadavi

Abrocitinib vs. Dupilumab for Atopic Dermatitis

Abrocitinib vs. Dupilumab will be an important question for many prescribing doctors with the expected FDA approval of abrocitinib soon.

We have extensively discussed atopic dermatitis (eczema) in the past. For many years only topical therapies were available for this condition. Topical steroids are the mainstays of treatment, and after many years newer topical therapies were developed such as Elidel and Eucrisa.

Eucrisa (crisaborole) New Eczema Medication gets FDA Approval

A breakthrough in eczema treatment occurred a few years ago with the development of Dupixent (Dupilumab). This is a systemic injectable medication that targets eczema from “within”. This was approved for moderate to severe atopic dermatitis.

Dupixent (Dupilumab) for Atopic Dermatitis/Eczema

Dupilumab has been a ground breaking treatment for eczema sufferers, as it has reversed many symptoms of patients who had a widespread distribution of atopic dermatitis and the topical therapies have failed them. Most patients with eczema do not want to take other therapies such as systemic steroids, immunosuppressants and/or phototherapy because of side effects.

We recently wrote about a new class of atopic dermatitis medication set to be released soon, these are the oral Janus kinase (JAK1) inhibitors. Abrocitinib will likely be the first one and it reduces interleukin-4 and interleukin-13 signaling.

Abrocitinib for Atopic Dermatitis by Pfizer

There will be others to follow as well. Baricitinib for Atopic Dermatitis (Eczema)

An important question to be answered is how will abrocitinib vs. dupilumab compare?

In the New England Journal of Medicine a study was published titled “Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis” investigated this question.

It was a phase 3 double-blind trial of patients with eczema that was unresponsive to topical agents to receive 200mg or 100mg of abrocitinib orally once daily, 300mg of dupilumab subcutaneously every other week (after a 600mg loading dose) or placebo. The endpoint was the Investigator’s Global Assessment (IGA) and an Eczema Area Severity Index-75 (EASI-75).

A total of 838 patients were enrolled. The results showed that the 200mg dose but not the 100mg dose of abrocitinib was superior to dupilumab with respect to itch at week 2. Neither abrocitinib dose differed significantly from dupilumab with respect to most other key secondary end point comparisons at week 16. Nausea occurred in 11.1% of patients in the 200mg abrocitinib group.

Based on this study abrocitinb vs. dupilumab long term did not show much of a difference up to 16 weeks for the 200mg dose. (This study was funded by Pfizer).

These 2 medications have very different administrations (daily oral vs. injectable every 2 weeks) and mechanisms of actions. But they will both be indicated for the same disease of moderate to severe atopic dermatitis. Choosing abrocitinib vs. dupilumab may also depend on the side effects of each medication if they have similar efficacy. We will find out more as more patients are enrolled in studies.

While this study provides insights about the differences of dupilumab vs. abrocitinib in the short term, longer term studies are required to understand the outcomes.  The author of the study Dr. Bieber said “This study confirms the impressive efficacy of abrocitinib in combination with topical therapies and appears to show distinct advantages in terms of the rapidity of itch relief compared to standard of care.”

New treatments for eczema on the horizon

New Eczema Medications in the Pipeline

Ruxolitinib for Eczema (atopic dermatitis)

 

 

Filed Under: atopic dermatitis, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page